BAT9 Inhibitors
Chemical inhibitors of BAT9 can affect the function of this protein through various signaling pathways by targeting specific kinases. Wortmannin and LY294002, as inhibitors of phosphoinositide 3-kinases, can prevent the activation of the AKT signaling pathway, which is integral for various cellular functions, including those involving BAT9. This inhibition halts the phosphorylation process, thereby reducing the functional capacity of BAT9. Similarly, PD98059 and U0126 disrupt the MAPK/ERK pathway by inhibiting MEK1/2, which can also lead to a decrease in BAT9 activity, assuming BAT9 is a downstream target of this pathway. The chemical SP600125, which targets the c-Jun N-terminal kinase (JNK), can lead to the inhibition of BAT9 if JNK signaling modulates its function. Furthermore, SB203580, an inhibitor of p38 MAP kinase, can impede BAT9 activity by interfering with p38 MAPK-mediated regulatory mechanisms, presuming that BAT9 is involved in such signaling cascades.
Continuing with the theme of kinase inhibition, PP2, which targets the Src family of kinases, can lead to the functional inhibition of BAT9 if Src kinases regulate its activity. Imatinib, by inhibiting BCR-ABL and other kinases, can affect BAT9 activity when these kinases are part of the signaling pathways governing BAT9. Sorafenib, a RAF kinase inhibitor, can also diminish BAT9 activity as part of the MAPK/ERK pathway's cascade, which often involves RAF kinases. Sunitinib, by inhibiting receptor tyrosine kinases like VEGFR, can alter the signaling pathways that regulate BAT9, resulting in its functional inhibition. Dasatinib, with its broad-spectrum tyrosine kinase inhibition, can impede the activation of kinases that are upstream regulators of BAT9. Lastly, Gefitinib, an EGFR tyrosine kinase inhibitor, can reduce BAT9 activity through its inhibition of EGFR and the subsequent signaling pathways that would ordinarily involve BAT9. Each of these inhibitors affects the functional state of BAT9 by impeding the activity of kinases that are critical to the signaling pathways that regulate BAT9 function.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, it prevents the activation of AKT signaling pathway, which is crucial for the survival and growth of cells. Inhibition of this pathway can lead to reduced activity of BAT9, as AKT can regulate the function of various proteins including BAT9 through phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another inhibitor of PI3K, and it operates similarly to Wortmannin. It prevents the phosphorylation and activation of AKT, thereby leading to decreased activity of downstream proteins that require AKT for activation or stabilization, including BAT9. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of the mitogen-activated protein kinase (MAPK/ERK) pathway by specifically inhibiting MEK1/2. BAT9, linked to the MAPK/ERK pathway, can be functionally inhibited when this pathway is downregulated, as the pathway is responsible for the regulation of a variety of cellular functions. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is also a selective inhibitor of MEK1/2, which are upstream regulators of the ERK pathway. By inhibiting this pathway, U0126 can result in the functional inhibition of BAT9, as the protein's activity can be dependent on signals propagated through ERK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in regulatory processes that can include proteins like BAT9. By inhibiting JNK, SP600125 can lead to the functional inhibition of BAT9 if it is regulated by JNK-mediated signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 serves as an inhibitor of p38 MAP kinase, which is involved in stress and inflammatory responses. If BAT9 activity is modulated by p38 MAPK signaling, inhibiting this kinase could lead to a functional inhibition of BAT9. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family kinases. Src kinases can regulate various cellular processes including those that involve BAT9. Inhibition by PP2 can thus lead to functional inhibition of BAT9 if it is dependent on Src signaling for its activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that targets BCR-ABL and other kinases. If BAT9 activity is influenced by tyrosine kinase signaling pathways that include these kinases, Imatinib can lead to its functional inhibition. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor targeting RAF kinases, among others. Since RAF is part of the MAPK/ERK pathway, inhibition of this pathway by Sorafenib may lead to decreased BAT9 activity if BAT9 is a downstream effector in this signaling pathway. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor. It can inhibit the vascular endothelial growth factor receptor (VEGFR) and related kinases. Inhibition of these receptors can affect signaling pathways that regulate proteins such as BAT9, leading to its functional inhibition. | ||||||